News from Bayer HealthCare Pharmaceuticals Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Oct 09, 2015, 10:29 ET Bayer Presents New Data on BETASERON® (interferon beta-1b) at ECTRIMS 2015

 Bayer HealthCare Pharmaceuticals Inc. announced today that new research studying BETASERON® (interferon beta-1b) will be...


Sep 14, 2015, 02:30 ET Bayer to Showcase Data from Growing Oncology Franchise at ECC2015 in Vienna

 Bayer HealthCare Pharmaceuticals Inc. announced today that data from its growing oncology portfolio will be presented at the 2015 European...


Sep 24, 2014, 02:30 ET ESMO 2014 to Feature New Oncology Data from Across Bayer Franchise

 Bayer HealthCare Pharmaceuticals Inc. announced today that data from its oncology portfolio, including Stivarga® (regorafenib) tablets,...


Sep 16, 2014, 02:30 ET Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer

 Bayer HealthCare and Orion Corporation, a pharmaceutical company based in Espoo, Finland, have begun to enroll patients in a Phase III trial...


Aug 13, 2014, 08:30 ET Over 1,000 Medical Sites in the United States Now Licensed to Administer Xofigo® (radium Ra 223 dichloride) Injection

Bayer HealthCare Inc. today announced that, approximately one year following the national launch, over 1,000 sites in the United States have...


Feb 18, 2014, 02:15 ET Bayer's Long-Acting Recombinant Factor VIII Demonstrated Prophylaxis with Less Frequent Infusions in Hemophilia A in Phase III Trial

Bayer HealthCare today announced positive results from the PROTECT VIII trial evaluating the company's investigational...


Nov 20, 2013, 11:14 ET Bayer's Third Annual Virtual Walk for Hemophilia Raises Funds, Brings Together the Hemophilia Community

 Bayer HealthCare and the National Hemophilia Foundation (NHF) today announced the successful conclusion of the third annual...


Sep 20, 2013, 07:40 ET Xofigo® (radium Ra 223 dichloride) Injection Recommended for Approval in the European Union

 Bayer HealthCare announced today that the the European Committee for Medicinal Products for Human Use (CHMP) recommended Xofigo® (radium...


Jul 17, 2013, 17:01 ET The New England Journal of Medicine Publishes Results from the Phase III ALSYMPCA Study of Xofigo® (radium Ra 223 dichloride) Injection

 Bayer HealthCare today announced that data from the pivotal Phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) trial of...


Jul 08, 2013, 04:28 ET Bayer Initiates Phase III Trial of an Investigational Recombinant Factor VIII Compound in Children with Hemophilia A

 Bayer HealthCare today announced the company has started to enroll patients in an international Phase II/III trial to evaluate its...


May 15, 2013, 18:01 ET Bayer to Present New Data Across Oncology Portfolio at ASCO 2013

Intended for U.S. Media Only -- Bayer HealthCare announced today that new data on the oncology portfolio, including Nexavar®...


May 15, 2013, 11:40 ET Bayer Receives U.S. FDA Approval for Xofigo® (radium Ra 223 dichloride) Injection as a New Treatment for Castration-Resistant Prostate Cancer with Bone Metastases

Intended for U.S. Media Only -- Bayer HealthCare announced today that the U.S. Food and Drug Administration (FDA) approved...


May 15, 2013, 02:30 ET Bayer Initiates Phase III Trial of Stivarga® (regorafenib) Tablets in Patients with Advanced Liver Cancer

Bayer HealthCare announced today that patient enrollment is underway for RESORCE (Regorafenib after Sorafenib in Patients with...


May 08, 2013, 08:00 ET Bayer to Present Data on Investigational Pulmonary Hypertension Compound Riociguat at ATS 2013

Bayer HealthCare announced today that data on its investigational pulmonary hypertension compound riociguat (BAY 63-2521) will be presented in a...


Apr 29, 2013, 02:30 ET Bayer to acquire Conceptus, Inc.

 Bayer intends to broaden its portfolio in the field of contraception. Thus, Bayer HealthCare LLC has signed a merger agreement with Conceptus,...


Apr 16, 2013, 05:00 ET Bayer Initiates Phase III Trial of Investigational Inhaled Amikacin Solution (BAY41-6551T) in Mechanically Ventilated Patients with Gram-negative Pneumonia

 Bayer HealthCare Pharmaceuticals Inc. announced today that patient enrollment is underway in its global Phase III trial program to evaluate...


Mar 25, 2013, 17:16 ET Bayer's Stivarga® (regorafenib) Tablets Approved in Japan

 Bayer HealthCare and Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) announced today that the Ministry of Health, Labor and Welfare (MHLW) in...


Feb 25, 2013, 16:05 ET Bayer's Stivarga® (regorafenib) Tablets Approved by U.S. FDA for Treatment of Patients with Locally Advanced, Unresectable or Metastatic GIST

 Intended for U.S. Media Only -- Bayer HealthCare and Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) announced today that the U.S. Food and...


Feb 13, 2013, 01:00 ET U.S. FDA Grants Priority Review to Bayer's Radium Ra 223 Dichloride NDA for Castration-Resistant Prostate Cancer with Bone Metastases

 Bayer HealthCare announced today that the New Drug Application (NDA) for its investigational oncology compound Radium Ra 223...


Dec 14, 2012, 08:01 ET Bayer Submits New Drug Application for Radium Ra 223 Dichloride for the Treatment of Castration-Resistant Prostate Cancer (CRPC) with Bone Metastases

 Bayer HealthCare today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA)...


Nov 28, 2012, 03:15 ET Bayer Announces Recruitment Achievement for Investigational Hemophilia Treatment

Bayer's BAY 86-6150 is being investigated in a Phase II/III study called TRUST (TReatment with Unique recombinant rFVIIa STudy), and the...


Nov 08, 2012, 11:11 ET Bayer's Second Annual Virtual Walk for Hemophilia Raises Funds, Generates Excitement in the Hemophilia Community

 At the National Hemophilia Foundation (NHF) Annual Meeting in Orlando today, Bayer HealthCare, the NHF and Save One Life celebrated the...


Oct 23, 2012, 16:33 ET Bayer's Investigational Riociguat Meets Primary Endpoint in Phase III Study of Patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

Bayer HealthCare today announced data from the Phase III CHEST-1 trial evaluating its investigational drug riociguat in patients with...


Oct 22, 2012, 19:30 ET Phase 3 Study Evaluates Two Investigational Hormone-Releasing IUDs for Prevention of Pregnancy for up to Three Years

Bayer HealthCare Pharmaceuticals Inc. today announced results of a Phase 3 study evaluating two investigational levonorgestrel-releasing...


Sep 13, 2012, 09:00 ET Study Published In Contraception Evaluates Medical Expenditures For Unintended Pregnancies And Potential Cost Impact Of Increased Use Of Long-Acting Reversible Contraception

 Bayer HealthCare Pharmaceuticals Inc. today announced that a new study published in the journal Contraception shows that if 10 percent...